K.H. GP HLDGS (01557) issues profit warning, expects interim loss of not more than HK$6 million, turning from profit to loss year-on-year.
K.H. GP HLDGS (01557) announces that the group expects to record a loss of not more than HK$6 million for the six months ended September 30, 2026, compared with a profit of approximately HK$152 million for the same period in 2025. The board believes that the expected turnaround from net profit to net loss is mainly due to the group's derecognition of its wholly-owned subsidiary K.H. Foundation Limited in the same period last year, which resulted in a gain on derecognition of approximately HK$162 million, and no such gain was recorded in the current period.
K.H. GP HLDGS (01557) announces that the group expects to record a loss of not more than HK$6 million for the six months ended September 30, 2026, compared with a profit of approximately HK$152 million for the same period in 2025. The board considers that the expected turnaround from net profit to net loss is mainly attributable to the gain of approximately HK$162 million recorded in the same period last year from the deconsolidation of its wholly-owned subsidiary Jianhong Foundation Limited, which did not recur during the current period.
Related Articles

YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.
YUM CHINA (09987) repurchased 35,600 shares on November 16 for approximately HK$14.1806 million.

GLOBAL BIO-CHEM (00809) intends to sell all equity interests in Changchun Dacheng Bio-Technology through public tender.

NIKE, Inc. Class B (NKE.US) lays out a clear growth path for the next five years: targeting US$5 billion in incremental revenue by fiscal 2031.






